Acerus Announces Resignation of Director Dec 26, 2022 07:00AM
Acerus Announces New Loan Agreement With First Generation Capital Dec 22, 2022 07:00AM
Acerus Reports Third Quarter 2022 Financial Results Nov 15, 2022 07:30AM
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders Oct 3, 2022 07:30AM
Acerus Announces Initiation of Strategic Review Sep 21, 2022 07:30AM
View Older Stories

Aug 23, 2022 07:30AM Acerus Announces Resignation of CFO Effective November 20, 2022
Aug 9, 2022 07:30AM Acerus Reports Second Quarter 2022 Financial Results
Aug 5, 2022 07:30AM Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders
Aug 3, 2022 07:30AM Acerus to Report Q2-2022 Financial Results and Host Investor Call
Jun 27, 2022 05:30PM Acerus Announces Voting Results for the 2022 Annual Meeting
Jun 24, 2022 07:30AM Acerus Announces Amendments to Loan Facility
Jun 7, 2022 07:30AM Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders
May 10, 2022 07:30AM Acerus Reports First Quarter 2022 Financial Results
May 5, 2022 07:30AM Acerus To Report Q1-2022 Financial Results And Host Investor Call
Apr 26, 2022 06:00PM Acerus Announces Completion of Share Consolidation
Apr 19, 2022 05:00PM Acerus Announces Share Consolidation
Mar 31, 2022 07:30AM Acerus Announces Amendments to Loan Facility
Mar 15, 2022 07:30AM Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 10, 2022 07:30AM Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
Mar 7, 2022 05:30PM Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™
Feb 28, 2022 07:30AM Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™
Feb 18, 2022 07:30AM Acerus Announces Amendment to Loan Facilities
Jan 10, 2022 07:30AM Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico
Dec 13, 2021 07:30AM Acerus Announces Amendments to Loan Facilities
Nov 9, 2021 07:30AM Acerus Reports Fiscal Third Quarter Financial Results
Nov 2, 2021 07:30AM Acerus to Report Q3-2021 Financial Results and Host Investor Call
Aug 23, 2021 07:30AM Acerus Announces Participation in HC Wainwright Conference
Aug 12, 2021 07:30AM Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
Aug 10, 2021 07:30AM Acerus Reports Fiscal 2021 Second Quarter Financial Results
Aug 3, 2021 07:30AM Acerus to Report Q2-2021 Financial Results and Host Investor Call
Jul 12, 2021 07:30AM Acerus Provides Update on Litigation with Recipharm
Jun 29, 2021 07:30AM Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States
Jun 14, 2021 05:30PM Acerus Announces Voting Results for the 2021 Annual Meeting
May 13, 2021 07:30AM Acerus Reports First Quarter 2021 Financial Results
May 10, 2021 07:30AM Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
May 6, 2021 07:30AM Acerus to Report Q1-2021 Financial Results and Host Investor Call
Apr 30, 2021 07:30AM Acerus Announces Closing of US$15 Million Secured Loan Facility
Apr 1, 2021 07:30AM Acerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu
Mar 30, 2021 07:30AM Acerus Announces Expansion of NATESTO® Distribution Worldwide
Mar 26, 2021 07:30AM Acerus Announces Amendment to Credit Agreement
Mar 11, 2021 07:30AM Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 4, 2021 07:30AM Acerus to Report 2020 Financial Results and Host Investor Call
Dec 24, 2020 07:30AM Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement
Nov 27, 2020 07:30AM Acerus Announces Details of Previously Completed Rights Offering
Nov 25, 2020 07:30AM Acerus Announces Completion of Over-Subscribed Rights Offering
Nov 3, 2020 07:30AM Acerus Reports Fiscal Third Quarter Financial Results
Oct 27, 2020 07:30AM Acerus to Report Third Quarter 2020 Financial Results and Host Investor Call
Oct 20, 2020 07:30AM Acerus Announces Rights Offering and Standby Commitment
Sep 29, 2020 05:00PM Acerus Announces Waiver of Third Quarter Financial Covenant in Credit Agreement
Sep 14, 2020 07:30AM Acerus Announces Addition of US Commercial Leader
Aug 11, 2020 07:00AM Acerus Reports Fiscal 2020 Second Quarter Financial Results
Aug 4, 2020 07:30AM Acerus to Report Second Quarter 2020 Financial Results and Host Investor Conference Call
Jul 28, 2020 07:30AM Acerus Announces Resumption of NATESTO® Shipments
Jul 21, 2020 07:30AM Acerus Announces Addition of Chief Medical Officer
Jul 20, 2020 07:30AM Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States
View Older Stories